文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

雾化前列环素在危重症患者中的应用及与临床结局的关联

Use of Aerosolized Prostacyclins in Critically Ill Patients and Association With Clinical Outcomes.
PubMed 文献 · Crit Care Explor · 2023-01-06
一句话结论回顾性队列显示雾化伊洛前列素与依前列醇均改善氧合,伊洛前列素组前12小时升压药需求更高,死亡率差异可能反映病情严重度不同。

该回顾性队列纳入2015至2018年俄克拉荷马大学健康科学中心ICU收治的126例因难治性低氧接受雾化依前列醇或伊洛前列素超过4小时的成人患者,其中伊洛前列素组95例(75%)、依前列醇组31例(25%)。主要终点为两组PaO2/FiO2比值变化,两组均显著改善;依前列醇组90天院内死亡率似乎更高,但研究未针对死亡率差异设计把握度,作者认为该差异可能反映依前列醇组病情更重及处方偏倚。伊洛前列素组给药后前12小时升压药需求更高,依前列醇组未见此关联。作者结论为两种肺血管扩张剂对气体交换改善相似,死亡率差异可能反映病情严重度差异,需进一步研究证实。

要点

  • 126例难治性低氧成人中,伊洛前列素95例(75%)、依前列醇31例(25%),两组PaO2/FiO2比值均显著改善。
  • 依前列醇组90天院内死亡率似乎高于伊洛前列素组,但研究未针对死亡率差异设计把握度,作者认为可能反映依前列醇组病情更重及处方偏倚。
  • 伊洛前列素组给药后前12小时升压药需求更高,依前列醇组未见此关联。
  • 作者结论:两种肺血管扩张剂对气体交换改善相似,死亡率差异可能反映病情严重度差异,需进一步研究证实。

适用人群与场景

  • 2015至2018年俄克拉荷马大学健康科学中心ICU收治的成人患者,因难治性低氧接受雾化依前列醇或伊洛前列素超过4小时者纳入分析。

研究设计与关键结果

  • 研究类型:回顾性队列分析;样本量126例;人群:ICU难治性低氧成人;干预:雾化伊洛前列素(95例,75%)vs 雾化依前列醇(31例,25%),均使用超过4小时。
  • 次要终点:依前列醇组90天院内死亡率似乎高于伊洛前列素组;但研究未针对死亡率差异设计把握度,作者认为该差异可能反映依前列醇组病情更重及处方偏倚。
  • 次要终点:伊洛前列素组给药后前12小时升压药需求更高,依前列醇组未见此关联。

证据类型、等级与局限

  • 证据类型:回顾性队列分析。
  • 局限:研究未针对死亡率差异设计把握度;依前列醇组病情可能更重及存在处方偏倚;需进一步研究证实。

对床旁实践的改变

  • 作者认为两种肺血管扩张剂对气体交换改善相似,死亡率差异可能反映病情严重度差异,需进一步研究证实。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Aerosolized prostacyclins are frequently used in patients with severe acute respiratory distress syndrome and refractory hypoxia. Previous studies have shown improvement in oxygenation with use of pulmonary vasodilators such as iloprost and epoprostenol; however, there is no head-to-head comparison between these agents.

OBJECTIVES: To compare the effects of inhaled epoprostenol and inhaled iloprost in critically ill patients with refractory hypoxia.

DESIGN SETTING AND PARTICIPANTS: We performed a retrospective cohort analysis of patients admitted to the ICUs at the University of Oklahoma Health Sciences Center between 2015 and 2018. Adult patients who received aerosolized epoprostenol or iloprost for more than 4 hours were included in the analysis.

MAIN OUTCOMES AND MEASURES: The primary endpoint measured was to compare the change in Pao2/Fio2 ratio between patients treated with iloprost compared with epoprostenol. Secondary outcomes measured were 90-day in-hospital mortality and improvement in vasopressor requirements.

RESULTS: A total of 126 patients were included in the study, 95 of whom received iloprost (75%) and 31 patients (25%) received epoprostenol. There were significant improvements in Pao2/Fio2 ratio in both the iloprost and epoprostenol group. Patients in the epoprostenol group appeared to have a higher 90-day mortality compared with the iloprost group. However, our study was not powered to detect a mortality difference and this finding likely represents a sicker population in the epoprostenol group and prescription bias. The use of iloprost was associated with higher vasopressor requirements in the first 12 hours of administration, an association was not observed in the epoprostenol group.

CONCLUSIONS AND RELEVANCE: In this retrospective cohort analysis, use of both pulmonary vasodilators was associated with similar improvement in gas exchange. The mortality difference observed likely represents difference in severity of illness. Further studies are needed to corroborate these findings.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Hussain ST, Jaliawala HA, Zhao D, et al. Use of Aerosolized Prostacyclins in Critically Ill Patients and Association With Clinical Outcomes. Crit Care Explor. 2023. PMID: 36699246. doi:10.1097/CCE.0000000000000845

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。